随着消费类企业不断登陆资本市场，资金对这些企业的认可力度正不断加大，这一点亦可在舒宝国际(02569)身上一窥究竟。 5月15日，舒宝国际午后强势拉升，从早盘的一个多点涨幅拉升至午盘的十几个点，而后愈走愈高，一度涨逾23%，截止收盘其股价大 涨22.22%至0.88港元。而拉长时间线来看，自5月6日以来其股价已经累涨超43%，而自上市(3月27日)以来，其股价则累涨超75%。 该公司作为晋江系企业，叠加"出海+母婴"概念，符合港股当下对高增长新兴消费股的偏好。其上市后股价持续攀升，反映市场对细分 赛道龙头的估值溢价。 2025年以来，消费类企业迎来上市高潮。以新式茶饮品牌为例，前有古茗、蜜雪集团分别于2月、3月赴港上市，后有霸王茶姬4月赴美 上市、沪上阿姨5月在港上市。不仅如此，港股市场还有纽曼思、布鲁可、舒宝国际等消费类企业完成上市。这里面，不少已上市和新 上市的"新消费"类企业股价均在强势上扬，反映出资金对这类企业的关注度正不断提升。 那么，搭上这一新概念的舒宝国际，投资价值究竟如何? 业务结构调整显著，营收增速放缓 据悉，舒宝国际成立于 2010 年，总部位于福建晋江，核心业务为一次性卫生用品的研发、生 ...

Core Viewpoint - CICC maintains profit expectations for Zhou Hei Ya (01458) for 2025 and 2026, raising the target price by 20% to HKD 3.0, indicating a potential upside of approximately 13.2% from the current price [1] Group 1: Store Quality and Structure - In 2025, the company will focus on enhancing store quality and optimizing store structure, emphasizing "people, goods, and environment" [2] - The company will enhance membership operations and attract traffic through online channels and in-store competitions among staff [2] - There are no specific targets for the number of stores in 2025, with a focus on improving store quality instead [2] - The store structure adjustment is expected to be completed by 2024, with a net reduction of 504 and 252 stores in commercial and community areas, respectively, while increasing transportation hub stores by 36 [2] - Same-store operations showed a year-on-year increase in Q1 2025 and April-May, indicating steady improvement in overall store performance [2] Group 2: Emerging Channels - The company is making steady progress in emerging channels, with products entering Sam's Club, Pang Donglai, and Yonghui stores [3] - In March 2024, the company's marinated products entered the Sam's Club channel, ranking in the Top 6 of the seasoning and sauce category by sales data [3] - The company has also entered Pang Donglai and some Yonghui stores, accelerating expansion into leading regional supermarkets [3] - Zhou Hei Ya has recently entered the MIX supermarket in Malaysia, laying a solid foundation for future expansion into Southeast Asia and other markets [3]

Group 1 - The Hong Kong stock market opened lower on May 19, with the Hang Seng Index down 0.73% and the Hang Seng Tech Index down 1.58% [1] - The Hong Kong Innovative Drug ETF (159567) rose by 0.58% with a turnover rate of 8.02% and a trading volume exceeding 1.15 billion yuan, indicating active trading [1] - The innovative drug ETF closely tracks the Hong Kong Stock Connect Innovative Drug Index, reflecting the performance characteristics of biotech companies listed in Hong Kong [1] Group 2 - The pharmaceutical sector has shown a strong rebound this year, with several pharmaceutical funds reporting net value increases exceeding 30% [1] - Institutions are focusing on investment opportunities in AI healthcare, brain-computer interfaces, and innovative drugs following a period of deep adjustment in the pharmaceutical sector [1] - Guojin Securities emphasizes that innovative drugs and certain semi-innovative drugs remain key investment areas, with upcoming policy changes and data releases expected to catalyze stock price movements [1] Group 3 - Guoxin Securities highlights the rapid growth phase of the innovative drug sector, driven by commercialization and external licensing, which is accelerating revenue growth and profitability [2] - The traditional Chinese medicine sector faces short-term pressure but retains long-term branding and innovation potential [2] - The medical device sector is under short-term pressure due to slow policy implementation and inventory issues, but there are expectations for recovery driven by improved bidding processes [2]

中国金融国际(00721.HK)早盘暴涨，一度涨近900%，现涨幅回落，涨超300%，报0.124港元，成交额 307.84万港元。 ...

Group 1 - The Hang Seng Technology Index has seen a decline of 2%, while the Hang Seng Index has dropped over 1% [1] - Tencent's stock performance is not mentioned, but the overall market sentiment indicates a bearish trend in the technology sector [1] - The stock of China Literature Limited (阅文集团) has decreased by nearly 7%, and Alibaba's shares have fallen by 4.7% [1]

智通财经APP获悉，远大医药(00512)高开逾3%，截至发稿，涨3.08%，报8.69港元，成交额796.87万港 元。 消息面上，继多款全球创新核药研发取得进展后，5月18日晚间，核药龙头远大医药再度传来重磅利 好，公司发布公告称，其位于成都温江的核药全球研发及生产基地已获得国家生态环境部颁发的甲级 《辐射安全许可证》，并将于2025年6月正式投入运营。该基地于2022年底签约，2023年4月全面启动环 评，同年11月获得施工许可正式破土动工，仅5个月实现主体封顶，以两年周期刷新了行业建设纪录， 且是目前全球核素种类最全、自动化程度最高的智能工厂之一。 根据公告，远大医药成都温江的核药全球研发及生产基地定位全球创新核药产业化高地，是全球首 个"零辐射"智能核药工厂，全流程辐射监测系统达到核电级安全标准。 该基地占地面积50亩，一期用地25亩，建设总面积超2.6万平方米，总规划投资拟超30亿元，聚焦同位 素工艺开发与制备、核药偶联技术、自动化标记技术等核心领域，覆盖核药早研、工艺开发、质量研 究、非临床研究、智能生产与精准配送一站式全生命周期管理，是目前国际范围内核素种类最全、自动 化程度最高的智能工厂之一 ...

Group 1 - The core point of the article is that the company,阅文集团 (00772.HK), experienced a decline of 4.73% in its stock price due to its removal from the Hang Seng Tech Index during the quarterly review of the Hang Seng Index [1] Group 2 - The removal from the Hang Seng Tech Index indicates a significant shift in the company's market position and may impact investor sentiment [1]

港股医药股走强，再鼎医药(09688.HK)涨超4%、康宁杰瑞制药-B(09966.HK)涨超2%、乐普生物- B(02157.HK)、四环医药(00460.HK)等跟涨。 ...

恒指低开0.81%，报23156.27点；恒生科技指数跌1.02%。阅文集团跌4.7%，阿里健康、阿里巴巴跌超 2.8%，京东健康跌2.1%。 ...

Group 1 - The Hong Kong pharmaceutical stocks are experiencing a strong performance, with Zai Lab (09688.HK) rising by 4.58% [1] - Other notable gainers include CStone Pharmaceuticals (09966.HK) increasing by 2.39% and Lepu Biopharma (02157.HK) up by 1.81% [1]